— Achieve Life Sciences (NASDAQ: ACHV) reported Q4 2019 net loss of $3.2 million, or $0.30 per share, compared to a loss of $3.6 million, or $0.55 per share, last year.
— Total operating expenses were $3.2 million.
— At December 31, 2019, cash, cash equivalents and restricted cash was $16.7 million.
— Achieve Life Sciences completed a meeting with the US FDA to finalize the Phase 3 cytisinicline clinical development program.
— The company established an agreement with the FreeMind Group to assist in securing non-dilutive funding to evaluate cytisinicline in vapers and e-cigarette users.
— The company closed an underwritten public offering for gross proceeds of $13.8 million, before underwriting discounts and commissions and offering expenses.
— ACHV shares were up 12.7% in premarket hours on Friday.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Vail Resorts (MTN) can reward investors once it gets past market crisis
The recent travel restrictions have taken a heavy toll on the tourism industry, leaving almost all destinations deserted. Vail Resorts Inc. (NYSE: MTN), a leading operator of mountain ski resorts,
The coming months will prove to be a testing time for Boeing (BA)
Shares of Boeing Co. (NYSE: BA) were up 13% in afternoon hours on Monday. The stock is down 63% from its 52-week high of $391. As the aviation industry suffers
Wayfair (W) stock looks less attractive despite low price, thanks to market selloff
Shareholders of online furniture retailer Wayfair Inc. (NYSE: W) have been speculating about their returns for long, with the stock not making any meaningful gains in the past several months.